Search Results - "Vey, N."
-
1
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Published in Leukemia (01-07-2011)“…The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS…”
Get full text
Journal Article -
2
Construction and preliminary validation of a tool to measure the needs of adolescents and young adults (AYA) diagnosed with cancer: the QUestionnaire nEEd Cancer AYAs: QUEEC-AYAs
Published in Health and quality of life outcomes (23-04-2024)“…In France, 2300 adolescents and young adults (AYAs, 15-25 years old) are diagnosed with cancer each year. As soon as the disease is diagnosed, a number of…”
Get full text
Journal Article -
3
Mutations of ASXL1 gene in myeloproliferative neoplasms
Published in Leukemia (01-11-2009)Get full text
Journal Article -
4
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
Published in Leukemia (01-05-2010)Get full text
Journal Article -
5
Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing
Published in Leukemia (01-04-2016)Get full text
Journal Article -
6
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
Published in Leukemia (01-04-2012)“…Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results…”
Get full text
Journal Article -
7
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML
Published in Bone marrow transplantation (Basingstoke) (01-04-2017)Get full text
Journal Article -
8
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
Published in Leukemia (01-06-2013)Get full text
Journal Article -
9
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
Published in Annals of oncology (01-08-2021)Get full text
Journal Article -
10
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
Published in Leukemia (01-12-2014)Get full text
Journal Article -
11
Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients
Published in Clinical microbiology and infection (01-02-2014)“…Cytomegalovirus (CMV) infection is a serious complication that may occur in the weeks or months following bone marrow transplantation. However, both…”
Get full text
Journal Article -
12
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
Published in European journal of haematology (01-04-2024)“…Objectives To compare the efficacy of venetoclax‐azacitidine (VEN–AZA) with AZA in the real‐life for patients with first relapsed or refractory acute myeloid…”
Get full text
Journal Article -
13
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Published in Leukemia (01-02-2010)Get full text
Journal Article -
14
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
Published in Leukemia (01-09-2007)“…Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of…”
Get full text
Journal Article -
15
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study
Published in Leukemia (01-03-2021)Get full text
Journal Article -
16
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
Published in Leukemia (01-06-2013)“…A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We…”
Get full text
Journal Article -
17
A new Leukemia Prognostic Scoring System for refractory relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
Published in Leukemia (01-06-2011)“…A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55…”
Get full text
Journal Article -
18
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT
Published in Bone marrow transplantation (Basingstoke) (01-05-2012)“…We previously reported that reduced intensity conditioning (RIC) regimen with fludarabine, BU and 2.5 mg/kg of rabbit anti-thymocyte globulin (r-ATG) was…”
Get full text
Journal Article -
19
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome
Published in Annals of hematology (01-04-2020)“…Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group…”
Get full text
Journal Article -
20
Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study
Published in Leukemia (01-02-2009)“…An early appreciation of treatment efficacy could be very useful in acute myeloblastic leukemia (AML), and a prognostic value has been suggested for the…”
Get full text
Journal Article